Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (AIRPORT-MPN)

A Phase 2 Pilot Randomized Controlled Trial Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

Myeloproliferative neoplasms (MPNs) are blood disorders that occur when the body makes too many white or red blood cells, or platelets. This overproduction of blood cells in the bone marrow can create problems for blood flow and lead to various symptoms. One of the major problems is the formation of blood clots. These may form in the veins of a patient's legs or arms where they cause leg or arm pain, swelling or difficulty walking. These clots may travel to the lung and then cause chest pain, shortness of breath and sometimes death. Blood clots can also lead to poor or no blood flow to one's heart, brain, or other organs, causing damages that cannot be easily or ever repaired, such as stroke or heart attack.

Patients diagnosed with certain types of MPN are associated with a higher risk of developing blood clots and related complications. For this reason, MPN patients are usually treated with low-dose aspirin, a common drug used for blood clot prevention, on long-term basis to prevent the formation of blood clots and other complications. However, recent studies also show that the risk of blood clots remains elevated in MPN patients treated with aspirin, and there may not be improvement or reduction in fatal or other events that are associated with blood clots. In addition, since this medical condition is rare, so there's a lack of studies done with high quality results to help physicians decide the best treatment plan for these patients.

The study drug, apixaban, is a new type of orally-taken blood thinner that has been shown to be effective and safe for prevention and treatment of blood clots in various patient populations. The investigators will evaluate whether apixaban is safer and/or better at preventing blood clots and other complications in MPN patients compared to aspirin.

Study Overview

• Status: Active, not recruiting
• Conditions: Primary Myelofibrosis; Venous Thromboembolism (VTE); Polycythemia Vera (PV); Essential Thrombocythemia (ET); JAK2 Mutation; Myeloproliferative Neoplasm (MPN)
• Intervention / Treatment: Drug: Aspirin 81 mg; Drug: Apixaban 2.5 MG Oral Tablet [ELIQUIS]

• Study Type: Interventional
• Enrollment (Actual): 44
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Aurelien Delluc, MD, PhD; Phone Number: 71069 613-737-8899; Email: adelluc@ohri.ca
• Study Contact Backup: Name: Anne Marie Clement; Phone Number: 73389 613-737-8899; Email: amclement@ohri.ca

Study Locations

• Canada
  • Ontario
    • Ottawa, Ontario, Canada, K1H 8L6
      • The Ottawa Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female subjects aged 18 years or older,
2. Confirmed diagnosis of PV, JAK2ET or JAK2 pre-fibrotic MF, per local clinical definitions
3. Able and willing to comply with study procedures and follow-up examinations contained within the written consent form

Exclusion Criteria:

1. Known allergy to apixaban or aspirin,
2. Another need for anticoagulation or specific anti-platelet therapy,
3. Contraindication to thromboprophylaxis (which would specifically include but not be limited to platelets less than 50x10^9/L and acquired Von Willebrand disease),
4. Current pregnancy or breast-feeding,
5. Renal dysfunction (Creatine Clearance <25 mL/min),
6. Known liver disease
7. Currently on any medication with a known interaction to apixaban
8. Unwilling to use an effective means of contraception for women of childbearing potential
9. Overtly fibrotic myelofibrosis
10. Myelodysplastic/myeloproliferative neoplasms

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Aspirin and cytoreductive therapy (if applicable); Patients who are randomized to this group will take a low-dose aspirin 81mg pill once per day (standard-of-care) for at least 6 months along with cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of his or her treating physician after the completion of the study.	Drug: Aspirin 81 mg; 81mg once per day for 6 months Then treated & followed up as per standard of care; Other Names: Acetylsalicylic acid
Experimental: Apixaban and cytoreductive therapy (if applicable); Patients who are randomized to this group will receive apixaban 2.5mg twice daily for at least 6 months along with standard intervention, cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of their treating physician after the completion of the study.	Drug: Apixaban 2.5 MG Oral Tablet [ELIQUIS]; 2.5mg twice per day for 6 months Then treated & followed up as per standard of care; Other Names: Eliquis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Average monthly subject recruitment rate of all study sites during a 6-month recruitment period		For the duration of study enrollment period: 6 months
Number of JAK2MPN patients recruited in 6 months in comparison to a target recruitment total of 39 prevalent cases and 5 incident cases at minimum		For the duration of study enrollment period: 6 months
Study Feasibility 1: Feasibility of recruitment	Feasibility of recruitment efforts will be determined by the proportion of patients contacted for screening versus those who are consented	For the duration of study enrollment period: 6 months
Study Feasibility 2: Feasibility of enrollment	Feasibility of enrollment will be determined by the proportion of patients consented vs those were enrolled and randomized	For the duration of study enrollment period: 6 months
Study Feasibility 3: Patient retention rate	This will be defined as the proportion of patients who started study intervention versus those who completed each of the study follow-up visits.	For the duration of the study follow-up period: 7 months
Quality of life on apixaban and aspirin will be measured through the use of the RAND 36-Item Health Survey (SF-36), with scores being transformed into a 0-100 scale where the higher the score the less disability.		For the duration of the study follow-up period: 7 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Study drug compliance as assessed by the proportion of study drug prescribed to the patient versus the actual amount study drug taken by the patient		For the duration of the study follow-up period: 7 months
Study visit compliance as assessed by the number of study visits (in person and/or phone call) completed		For the duration of the study follow-up period: 7 months
Percentage of incident and prevalent cases included in the study		For the duration of study enrollment period: 6 months
Rate of combined arterial and venous thrombotic events (MI, stroke, transient ischemic attack, peripheral arterial thrombosis, VTE)	This will be defined as the total number of arterial and venous thrombotic events developed relative to the total number of patients who received study treatment	For the duration of the study follow-up period: 7 months
Rate of major bleeding as per the International Society of Thrombosis and Hemostasis definitions	This will be defined as the total number of adjudicated major bleeding events relative to the total number of patients who received study treatment	For the duration of the study follow-up period: 7 months
Rate of non-major clinically relevant bleeding as per the International Society of Thrombosis and Hemostasis definitions	This will be defined as the total number of adjudicated non-major clinically relevant bleeding events relative to the total number of patients who received study treatment	For the duration of the study follow-up period: 7 months
Rate of all-cause mortality	This will be defined as the total number of adjudicated deaths relative to the total number of patients who received study treatment	For the duration of the study follow-up period: 7 months

Collaborators and Investigators

• Sponsor: Ottawa Hospital Research Institute
• Collaborators: Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network; the Association médicale universitaire de l'Hôpital Montfort (AMUHM); Canadian Hematology Society
• Investigators: Principal Investigator: Aurelien Delluc, MD, PhD, The Ottawa Hospital; Principal Investigator: Miriam Kimpton, MD, The Ottawa Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 17, 2021
• Primary Completion (Estimated): December 31, 2023
• Study Completion (Estimated): December 31, 2023

Study Registration Dates

• First Submitted: January 6, 2020
• First Submitted That Met QC Criteria: January 23, 2020
• First Posted (Actual): January 28, 2020

Study Record Updates

• Last Update Posted (Actual): August 1, 2023
• Last Update Submitted That Met QC Criteria: July 30, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Neoplasms by Site; Bone Marrow Diseases; Hematologic Diseases; Hemorrhagic Disorders; Embolism and Thrombosis; Blood Coagulation Disorders; Blood Platelet Disorders; Bone Marrow Neoplasms; Hematologic Neoplasms; Neoplasms; Primary Myelofibrosis; Thrombocytosis; Thrombocythemia, Essential; Thromboembolism; Venous Thromboembolism; Myeloproliferative Disorders; Polycythemia Vera; Polycythemia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Fibrinolytic Agents; Fibrin Modulating Agents; Platelet Aggregation Inhibitors; Cyclooxygenase Inhibitors; Antipyretics; Protease Inhibitors; Factor Xa Inhibitors; Antithrombins; Serine Proteinase Inhibitors; Anticoagulants; Aspirin; Apixaban
• Other Study ID Numbers: AIRPORT-MPN-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No